Contact
Header_1077x260px_About_Profil.jpg

D4kids: Profil joined a new pan-European Artificial Pancreas initiative

Profil is part of the new Diabeloop for children (D4kids) pan-European consortium for functionally enhancing an Artificial Pancreas (AP) system to better serve the needs and requirements of children with type 1 diabetes (T1D) and their families.

Based on a co-creative approach and clinical evidence D4kids will adapt the AP system with the ambition to

  • ameliorate the long-term trajectories of T1D
  • enhance the quality of life of children and their families
  • boost pediatric care
  • improve the sustainability of European healthcare Systems
Read More

Topics: About Profil, Treating Diabetes

Posted by Prof. Dr. Freimut Schliess on May 2, 2018 4:53:00 PM
prof-dr-freimut-schliess

Artificial pancreas for type 2 diabetes: the CLOSE project

There is a great and ever increasing socioeconomic burden on Europe due to the prevalence of people with multiple chronic diseases. CLOSE (Automated glucose control at home for people with chronic disease) serves to innovate homecare for insulin treated patients with type 2 diabetes mellitus (T2DM) by offering an integrated product and service package (AP+). Blood glucose levels will be controlled by an artificial pancreas (AP) that will be installed at the patients' home, operated through trained caregivers, and remote controlled (telehealth).

Read More

Topics: Clinical Trials in Diabetes, Treating Diabetes

Posted by Prof. Dr. Freimut Schliess on Jan 18, 2018 5:03:00 PM
prof-dr-freimut-schliess

Glucose Clamps: 2 steps towards hepatic and peripheral insulin sensitivity

Context

The hyperinsulinemic euglycemic clamp is the gold standard required by regulatory authorities for quantifying the glucodynamics of insulin preparations in clinical trials. Glucose clamping avoids confounding effects due to fluctuations in blood glucose concentrations as seen in the insulin tolerance test.

The hyperinsulinemic euglycemic clamp is also the method of choice for measuring human insulin sensitivity in clinical trials (deFronzo et al., 1979; Heise & Heinemann, 2001; Heise et al., 2016). Today CE-labeled medical devices like ClampArt® are available. ClampArt® takes advantage from an intravenous (iv) continuous blood glucose monitoring and a smart algorithm.

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Aug 9, 2017 5:00:00 PM
prof-dr-freimut-schliess

InnoDiaCare: Summer School for Digital Innovation in Diabetes Care

Profil is proud to be part of the InnoDiaCare Summer School which is partnering with the CLOSE EIT Health innovation project on automated glucose control at home for patients with type 2 diabetes mellitus.

The InnoDiaCare Summer School for Digital innovation in Diabetes Care will be held in Poland (July) and in Germany (August). It is aimed at students and graduates to master their entrepreneurial skills and to empower them to create new business ideas on digital diabetes management.

Read More

Topics: Events

Posted by Prof. Dr. Freimut Schliess on May 5, 2017 5:00:00 PM
prof-dr-freimut-schliess

Glucose clamps: 2 steps towards insulin sensitivity adjusted for glucose effectiveness

Context

When adopting a glucocentric view on diabetes the hyperinsulinemic euglycemic clamp sets the gold standard for recording insulin sensitivity and time-action profiles in clinical trials (deFronzo et al., 1979; Heise & Heinemann, 2001; Heise et al., 2016). Both assessments capture the decrease of blood glucose levels following administration of exogenous insulin which again reflects the modulation of cellular glucose uptake and metabolism exerted by the hormone. Compensating for the insulin-induced decrease of blood glucose levels by clamping a defined blood glucose concentration helps to avoid effects related to fluctuating blood glucose concentrations and the physiological response to hypoglycemic states which would confound insulin sensitivity assessment. 

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Mar 16, 2017 4:53:00 PM
prof-dr-freimut-schliess

Liver first ? Part III: Medical Needs

In part II and part I of this series you read about the lessons learnt from preclinical work with respect to NASH and NAFLD. In this last part we will look at the medical needs, possible interventions and clinical trials in this area. Enjoy reading and don't forget to register for our monthly blog mailer (to the right of this page) so you won't miss future posts. 

Medical needs

Lifestyle interventions. Although lifestyle changes have been recognised to be a cornerstone in the prevention of diabetes, fatty liver, NASH and cardiovascular disease (Barb et al., 2016) sustainable regimes are difficult to implement and often hamper from a limited compliance of targeted people. There is a general gap between the broad availability of quality information on the impact of livestyle for health promotion and chronic disease prevention on the one hand, and the translation of into behavioural attitudes on the other.

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Dec 9, 2016 5:01:00 PM
prof-dr-freimut-schliess

Liver first ? Part II: NASH and NAFLD

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Dec 1, 2016 12:21:15 PM
prof-dr-freimut-schliess

Business Trends in Diabetes Care

"How should business models in the field of diabetes homecare in the future look like?“

From August 22nd to October 7th, 26 students from the Center of Digital Technology and Management (CDTM) in Munich started to address this question during a 7-week Trend Seminar which has been co-organised by Profil.

Read More

Topics: About Profil

Posted by Prof. Dr. Freimut Schliess on Aug 24, 2016 5:00:00 PM
prof-dr-freimut-schliess

Liver first? The liver in diabetes and cardiovascular disease (Part I)

The liver‘s specific anatomical conditions and functions in systemic metabolism and defense provoke a hepato-centric view on the pathogenesis and treatment of diabetes. Whereas the contribution of the liver as a glucose supplier to the development of hyperglycaemia and associated comorbid conditions is well recognised (DeFronzo, 2009) its involvement beyond the provision of too much glucose has been unravelled more recently (Stefan & Häring, 2013).

Read More

Topics: The Science behind Diabetes

Posted by Prof. Dr. Freimut Schliess on Jul 20, 2016 3:24:12 PM
prof-dr-freimut-schliess

Profil Science Report 2015 is now available

A tradition of scientific excellence lives on

A strong scientific profile is key to Profil Germany's success. Over the past years, Profil has published many scientific articles, books, and book chapters. We have contributed numerous oral and poster presentations at the relevant conferences around the world. Our customers value this scientific competence and when we present study results they benefit from the good reputation that "their" CRO enjoys. In line with the goal to maintain a high scientific impact in the community, Profil started to compile a yearly "Science Report" a few years ago.

Read More

Topics: About Profil

Posted by Prof. Dr. Freimut Schliess on Dec 22, 2015 2:00:00 PM
prof-dr-freimut-schliess

Subscribe to our monthly blog updates

Find out more: Glucose Clamp Webinar

Subscribe to Email Updates

Our most popular Posts